The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature
INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft tissue sarcoma subtypes [10] and a phase III [11] clinical trial followed resulting in FDA approval in 2012...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Sciendo
2015-09-01
|
| Ráidu: | Forum of Clinical Oncology |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1515/fco-2015-0012 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|